Component
Ischemic stroke incidence
Independently recorded substance, clinical endpoint or assay readout. Claims retain study-specific population and measurement context.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
First ischemic stroke was lower with combined treatment (HR 0.76; 95% CI 0.64–0.91); hemorrhagic stroke, MI and all-cause death did not differ significantly.
Experimental context and source evidence
- experimental_model
- Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype.
- exposure
- Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years.
- limitations
- Secondary endpoints, event frequency and confidence intervals matter; null results do not prove identical risks.
- nutrient_topic
- Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. · Folate (vitamin B9)
- organism
- Homo sapiens
- plain_language
- The benefit was endpoint-specific, rather than a uniform reduction in every vascular event.
- primary_references
- [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
- tissue_or_cell_type
- Human blood or whole-person clinical endpoints
Folate and folic acid: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1605–1615
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. · source_derived_draft · unverified_draft
### fol-csppt-ischemic-stroke First ischemic stroke was lower with combined treatment (HR 0.76; 95% CI 0.64–0.91); hemorrhagic stroke, MI and all-cause death did not differ significantly. Condition category: normal nutrient_topic: Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The benefit was endpoint-specific, rather than a uniform reduction in every vascular event. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person clinical endpoints experimental_model: Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. limitations: Secondary endpoints, event frequency and confidence intervals matter; null results do not prove identical risks. exposure: Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years. [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.